Telix Shares Surge Following Surprise Deal with Regeneron
Telix Pharmaceuticals (ASX:TLX) has seen a significant rise in its share price following an unexpected partnership with Regeneron, a major player in the biopharmaceutical industry. The deal has sent shares up by as much as 9%, surprising many investors and short sellers alike.
The collaboration involves developing nuclear medicine cancer therapies targeting “multiple solid tumour targets” within the biologics sector. This agreement is with Indianapolis-based Regeneron, a company with a market capitalisation of US$80 billion. Regeneron specialises in inventing, developing, and commercialising life-transforming medicines for people with serious diseases.
This partnership combines Telix’s expertise in radiopharmaceutical development and manufacturing with Regeneron’s capabilities in antibody discovery and oncology experience. Biologics, which are complex medications derived from living organisms, are at the core of this initiative.
The initial financial terms of the deal include a US$40 million upfront payment to Telix for four initial programs. The company has the option to co-fund commercialisation and development, potentially earning up to a total of US$2.1 billion in development and commercial milestones. Additionally, Telix could receive low double-digit royalties.
Alternatively, if Telix chooses not to co-fund a particular program, it could still earn up to US$535 million in development and commercial milestones, along with royalties. Regeneron also has the option to expand the collaboration to four additional programs, with further upfront payments for Telix.
The two companies will jointly develop diagnostic assets, with Telix leading commercialisation and Regeneron receiving a set percentage of profits. Telix CEO Dr Chris Behrenbruch highlighted the significance of the collaboration, stating that it represents a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics-based radiopharmaceuticals can do for patients.
While the specific cancer indications have not been disclosed, Regeneron’s senior vice president, Dr Israel Lowy, mentioned interest in targeted radiopharmaceuticals, which could be used as monotherapies or in combination with Regeneron’s immunotherapy platform. The focus is on areas with high unmet patient needs, such as lung cancer.
Monash IVF Group Considers Improved Takeover Proposal
Monash IVF Group (ASX:MVF) is currently evaluating an improved indicative takeover proposal from a consortium consisting of Genesis Capital Investment Management and Washington H Soul Pattinson (ASX:SOL). This comes after a rejected proposal was submitted in November.
The new offer includes a cash payment of 90 cents per share via a scheme of arrangement, compared to the previous 80 cents. This valuation places the company at $350 million. The board is assessing the proposal, including seeking advice from its financial and legal advisers.
The bidders have stated that their price is the highest they are willing to offer, absent a competing proposal. The offer is valid until close of business on the following Tuesday, adding urgency to the situation.
The bid depends on several factors, including the board’s endorsement. Given that the consortium holds 19.6% of the Monash IVF register, no other party can proceed without their approval.
Monash IVF shares have shown a positive trend, rising as much as 19% to 80 cents. This follows a period of decline after revelations of an embryo mix-up at a Brisbane clinic a year ago. The stock hit a seven-year high of $1.50 in March 2024.
Board Tilt at Arovella Therapeutics
A trio of prominent biotech names is behind a board tilt at cancer cell therapy developer Arovella Therapeutics (ASX:ALA). The Trust Company (Australia) Limited intends to force a shareholder meeting to elect David Williams, Mark Diamond, and Michael Thurn as directors.
As the holder of more than 5% of Arovella, The Trust Company can initiate this under section 249D of the Corporations Act. David Williams chairs the investment bank Kidder Williams and oncology play Inoviq (ASX:IIQ). Mark Diamond chairs kidney drug developer Dimerix (ASX:DXB), while Michael Thurn was previously CEO of motor neuron disease drug developer Neurizon Therapeutics (ASX:NUZ).
Arovella is currently deciding the validity of the “purported” notice. If deemed valid, the company must call a meeting within 21 days and hold it within two months. The board notes that the resolution does not include a proposal to remove any existing Arovella directors.
Pro Medicus Secures Major Contract Renewal
Pro Medicus (ASX:PME) has renewed a five-year, $37 million contract with the Chicago-based hospital system, Northwestern Medicine. The deal involved increased minimum payments and higher fees per transaction.
Diligent readers will recall that the company recently unveiled a five-year $23 million contract with the University of Maryland Medical System. CEO and co-founder Dr Sam Hupert highlighted the importance of client retention, stating that the renewed contracts demonstrate the value of their solutions.
Pro Medicus shares have experienced some volatility but have gained 7% over the last week.
